T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease.

Pharmaceutical

T3D Therapeutics

John Didsbury

Jessica Stanek

Hoda Gabriel

Blake Swearingen

Stan Chamberlain

Warren Strittmatter

T3D Therapeutics was founded by a team with experience in the medical, pharmaceutical, and research industries. The team has worked at companies such as Oculus Research, GlaxoSmithKline, Talecris Biotherapeutics, and DARA BioSciences. They have also held positions such as President & CEO, Head of Strategy and Operations, and Deputy Director of Clinical Development. The team is also highly educated, with degrees from North Carolina State University, The Robert Larner College of Medicine, and the University of Connecticut.

Leadership Team

Board of Directors

CEO and Executive Team

Leadership Team

About

Team members

Other teams at T3D Therapeutics

Board of Directors

CEO and Executive Team